RVPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Reviva Pharmaceuticals (RVPH) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows weak technical indicators, negative financial performance, and lacks strong positive catalysts. Additionally, the recent reverse stock split and analyst downgrade further suggest caution.
The technical indicators for RVPH are bearish. The MACD is below 0 and negatively contracting, the RSI indicates the stock is oversold at 13.406, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading near its key support level at 0.82, but overall trends suggest continued weakness.
Proceeds will be used for research activities, including the RECOVER-2 Phase 3 trial for schizophrenia.
The company recently underwent a 1-for-20 reverse stock split, which is often associated with weak share price performance and attempts to maintain exchange listing compliance. Analysts have downgraded the stock to Hold, citing historical trends of continued pressure following reverse splits. The stock has also shown significant volatility, with a 52-week range of $1.82 to $23.4.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop of -52.06% YoY to -$4,010,773, and a significant EPS decline of -76.00% YoY to -0.06. Gross margin remains at 0%. Overall, the financial performance is weak.
D. Boral Capital downgraded RVPH to Hold from Buy, citing concerns over the reverse stock split and its historical association with weak stock performance. No recent price target changes were noted.
